As of January 1, 2026, Medi-Cal no longer covers GLP-1 medications for weight loss for members 21 and older, though it still covers them for Type 2 diabetes
Overall, the results of this study indicate that LY3437943 has a safety and tolerability profile similar to other incretins, with pharmacokinetic and pharmacodynamic outcomes that support further clinical evaluation
Eli Lilly to seek approval for powerful new obesity drug retatrutide in early 2027 Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027 after successful late-stage trials
So its fantastic that people are finally paying attention. Stepping back to look at the opportunity in snacks, he says, I see Ozempic accelerating the pace of the better for you trend, which has focused on macros like higher protein, less sugar, but I think its also going to really drive interest in truly functional foods. Formulating with resistant starch As with any functional ingredient, meanwhile, he cautions, we should pay attention to how much is being used and whether the food matrix or formulation helps or hinders the active ingredients
